Ohad Hammer
Contributor since: 2007
Latest Articles
Incyte's Jakafi Is Likely A $1 Billion Drug
Onyx - A 'Must Own' Biotech For 2013
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
ASH 2012 Preview: Top Picks For Upcoming Blood Cancer Meeting
AVEO Pharmaceuticals: Attractive Following Recent De-Risking Events
Winners Of ESMO 2012
Exelixis: First Partnered Program Enters Phase III
Seattle Genetics: Positive Read-Through From Roche's Investor Day
Upcoming Catalysts For Exelixis And Immunogen
Synta - The Signal Looks Real
Winners Of ASCO 2012
Drugs To Watch At ASCO 2012
Gilead's Hematology Pipeline: Transformative And Under-Appreciated
Threshold Scores Big With Pancreatic Cancer Data
Biotech Stocks To Watch In 2012
Arqule's Strategy Continues To Generate Value
AVEO: More Open Questions Than Answers
5 Winners Of American Society Of Hematology 2011
Pfizer's Xalkori: The Story Can Only Get Better
Exelixis: Setting The Facts Straight
Micromet Unveils Another Fast Route To Market, Marks Pfizer As Lead Competitor
Bristol-Myers Squibb Zeroes In On A Blockbuster Cancer Drug
Exelixis: Still Promising, Still Controversial
Celldex's Vaccine Gets a Boost
Why It's Time to Sell ImmunoGen
5 Oncology Drugs Available for Partnering (Part II)
Drugs to Watch at ASCO 2011
5 Oncology Drugs Available for Partnering
Putting a Price Tag on Synta's Lead Drug Activities
Morphosys' Growth Story Remains Intact
Exelixis: Going Where No Drug Has Gone Before
As Seattle Genetics Strengthens Its Foothold Within Genentech, What About Immunogen?